Jordan Stanley C, Toyoda Mieko, Vo Ashley A
Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Transplantation. 2009 Jul 15;88(1):1-6. doi: 10.1097/TP.0b013e3181a9e89a.
Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 25 years. IVIG products are also effective in the treatment of autoimmune and inflammatory disorders; however, the precise mechanism(s) of action is not known. Recent investigations suggest that IVIG has a much broader ability to regulate cellular immunity including innate and adaptive components. IVIG is also a recently recognized modifier of complement activation and injury. Here, we discuss these important advancements and how this knowledge applies to desensitization protocols and to the treatment of antibody-mediated rejection.
静脉注射免疫球蛋白（IVIG）产品源自混合人血浆，已用于治疗原发性免疫缺陷疾病超过25年。IVIG产品在治疗自身免疫性和炎性疾病方面也有效；然而，确切的作用机制尚不清楚。最近的研究表明，IVIG具有更广泛的调节细胞免疫的能力，包括先天性和适应性成分。IVIG也是一种最近被认识的补体激活和损伤调节剂。在此，我们讨论这些重要进展以及这些知识如何应用于脱敏方案和抗体介导的排斥反应的治疗。
